These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9081325)

  • 1. [Lymphoma in the elderly].
    Coiffier B
    Bull Cancer Radiother; 1996; 83(4):265-8. PubMed ID: 9081325
    [No Abstract]   [Full Text] [Related]  

  • 2. Non Hodgkin's lymphomas: prognostic feature of 55 patients treated with MEVAP chemotherapy.
    Mazza P; Lauria F; Gherlinzoni F; Fiacchini M; Galieni P; Tura S
    Haematologica; 1984; 69(2):178-87. PubMed ID: 6429003
    [No Abstract]   [Full Text] [Related]  

  • 3. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-Hodgkin lymphomas of the head and neck, stages I and II. Apropos 35 cases].
    Touboul E; Ghenim C; Chantelar JV; Nizri D; Zribi A; Guerin RA; Guilbert F; Bertrand JC; Szpirglas H; Beral HM
    Rev Stomatol Chir Maxillofac; 1985; 86(5):300-9. PubMed ID: 3868001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thyroid lymphoma. A medical emergency].
    Manresa JM; Contreras E; Caballol R; Sirvent JJ
    Med Clin (Barc); 1992 May; 99(1):38-9. PubMed ID: 1602902
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of malignant lymphoma with extranodal lesions--indications and timing for local therapies].
    Kinoshita T; Kagami Y
    Rinsho Ketsueki; 1999 Mar; 40(3):192-5. PubMed ID: 10222624
    [No Abstract]   [Full Text] [Related]  

  • 8. Infusions, age, and drug doses: redux.
    Coleman M; Boyd DB
    J Clin Oncol; 1988 Apr; 6(4):751. PubMed ID: 2451714
    [No Abstract]   [Full Text] [Related]  

  • 9. Increasing chemotherapy intensity in aggressive lymphomas: a renewal?
    Coiffier B
    J Clin Oncol; 2003 Jul; 21(13):2457-9. PubMed ID: 12829662
    [No Abstract]   [Full Text] [Related]  

  • 10. [Primary breast lymphoma].
    Cohen Y; Goldenberg N; Kasis S; Shpilberg D; Oren M
    Harefuah; 1993 Jul; 125(1-2):24-6, 63. PubMed ID: 8225062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic results of 36 malignant lymphomas and 8 histiocytic medullary reticulosis in childhood].
    Shimizu Y; Hashida T; Esumi N; Morioka Y; Nagai T; Arakawa S; Imashuku S; Fushiki S; Ikuta H; Miyake M
    Rinsho Ketsueki; 1984 Nov; 25(11):1738-45. PubMed ID: 6549474
    [No Abstract]   [Full Text] [Related]  

  • 12. What is your diagnosis? Ocular lymphoma.
    Cave T; Billson M
    J Small Anim Pract; 2003 Dec; 44(12):523, 553-4. PubMed ID: 14692547
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Kosmas C; Malamos NA; Antonopoulos MJ
    N Engl J Med; 1998 Nov; 339(20):1476; author reply 1477. PubMed ID: 9841319
    [No Abstract]   [Full Text] [Related]  

  • 14. When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)? The French Cooperative Group on C.L.L.
    Binet JL
    Hematol Oncol; 1993; 11 Suppl 1():38. PubMed ID: 8486339
    [No Abstract]   [Full Text] [Related]  

  • 15. Bilateral primary renal lymphoma.
    James TC; Shaikh H; Escuadro L; Villano JL
    Br J Haematol; 2008 Oct; 143(1):1. PubMed ID: 18513283
    [No Abstract]   [Full Text] [Related]  

  • 16. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Mounier N; Gisselbrecht C; Lepage E
    N Engl J Med; 1998 Nov; 339(20):1476; author reply 1477. PubMed ID: 9841320
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemotherapy is an effective first line treatment for early stage gastric mucosa-associated lymphoid tissue lymphoma.
    Yoon SS; Hochberg EP
    Cancer Treat Rev; 2006 Apr; 32(2):139-43. PubMed ID: 16524666
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical features of extranodal malignant lymphoma--staging classification and treatment strategies].
    Takagi T
    Rinsho Ketsueki; 1999 Mar; 40(3):188-91. PubMed ID: 10222623
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.